The Amicus facility encompasses 75,000 square feet of the top three floors of a new building located on Market Street in Philadelphia. The space includes office space, as well as state-of-the-art laboratories. It’s expected to provide space for approximately 200 researchers and drug developers focused exclusively on gene therapies.
We have been covering the biomanufacturing workforce at length this year because it remains one of the most important topics for companies in today’s near full-employment job market.
Philadelphia, the birthplace of cell and gene therapy, is home to a number of companies focused on developing multiple treatment options for rare diseases, those that affect less than 200,000 people in the United States.
Philadelphia is not just the city of brotherly love. It is one of the nation’s top biopharma hubs and the birthplace of cell and gene therapy. Within the next few years, the role of life sciences companies and institutions that call the city home is expected to grow at an accelerated rate, further cementing the city’s place as a key biopharma ecosystem.
